RTP Mobile Logo
Submitted by web@researchtop... on Mon, 02/04/2019 - 12:46
FLUpdate119

Interview with Nathan H Fowler, MD

Track 1: Overview of current treatment approaches in follicular lymphoma (FL)
Track 2: Mechanism of action of the anti-CD20 antibodies rituximab and obinutuzumab
Track 3: Activity of lenalidomide and possible correlation of cereblon expression with response in FL
Track 4: Inhibition of the PI3-kinase pathway in low-grade lymphomas
Track 5: Activity of BTK inhibitors in FL
Track 6: Rationale for the Phase III RELEVANCE trial: Lenalidomide/rituximab (R2) versus rituximab/chemotherapy, each followed by maintenance rituximab, as first-line therapy for FL
Track 7: Design of the RELEVANCE study for patients with previously untreated FL
Track 8: Duration of up-front R2 and maintenance rituximab
Track 9: Adherence to long-term lenalidomide therapy
Track 10: Perspective on the 3-year progression-free survival results from the RELEVANCE trial
Track 11: Tolerability of R2 versus rituximab/chemotherapy
Track 12: Clinical experience with lenalidomide-associated neutropenia, rash and diarrhea
Track 13: Second-line therapy options for patients who receive first-line R2
Track 14: Case: A 52-year-old woman with symptomatic Grade I/II FL attains a complete remission (CR) with first-line R2 therapy
Track 15: Case: A 53-year-old woman who previously received several lines of therapy, including R-CHOP, BR, R2 and idelalisib, receives chimeric antigen receptor (CAR) T-cell therapy on a clinical trial
Track 16: Activity of CAR T-cell therapies in FL
Track 17: Potential synergy of lenalidomide and CAR T-cell therapy
Track 18: Activity of idelalisib for patients with FL
Track 19: Side effects and quality of life with idelalisib
Track 20: Case: A 73-year-old woman with relapsed/refractory FL receives copanlisib
Track 21: Selection of PI3-kinase inhibitor for patients with FL
Track 22: Risks and benefits with idelalisib versus copanlisib
Track 23: Treatment options for patients with FL and early disease relapse
Track 24: Case: A 43-year-old man presents with Grade IIIA FL, receives R-CHOP and experiences a CR lasting for 5 years
Track 25: Response to second-line lenalidomide/obinutuzumab
Track 26: Perspective on the use of CAR T-cell therapy or immune checkpoint inhibition for patients with transformed FL

Interview with Gilles A Salles, MD, PhD

Track 1: Case: A 56-year-old man with Stage IV FL achieves a CR with the R2 regimen as first-line therapy on a clinical trial
Track 2: Therapeutic approach to Grade III FL
Track 3: Deciding between treatment and observation for patients with newly diagnosed FL
Track 4: RELEVANCE: A Phase III trial evaluating R2 versus rituximab/chemotherapy, each followed by maintenance rituximab, for previously untreated FL
Track 5: Dosing and administration schedule of the R2 regimen
Track 6: Side effects and quality of life with R2 versus rituximab/chemotherapy
Track 7: Activity and tolerability of R2 in patients with untreated FL
Track 8: Case: A 78-year-old woman who receives idelalisib for relapsed FL experiences gastrointestinal and hepatic toxicity
Track 9: Efficacy and tolerability of idelalisib
Track 10: Monitoring and management of hepatic toxicity and neutropenia associated with idelalisib
Track 11: Risk of opportunistic infections and colitis with idelalisib
Track 12: Comparison of the PI3-kinase isoforms targeted and the tolerability of idelalisib, duvelisib and copanlisib
Track 13: Perspective on the differences in efficacy among PI3-kinase inhibitors
Track 14: Hyperglycemia associated with copanlisib
Track 15: Therapeutic options for patients with relapsed FL
Track 16: Approach to patients with FL who experience relapse early in their treatment course
Track 17: Perspective on the efficacy of obinutuzumab-based chemotherapy versus rituximab-based chemotherapy for FL
Track 18: Case: A 44-year-old man receives rituximab for Stage II FL and experiences disease transformation to diffuse large B-cell lymphoma
Track 19: Efficacy of CAR T-cell therapy for patients with FL
Track 20: Case: A 55-year-old man experiences a prolonged CR after receiving rituximab for relapsed FL
 
FACULTY
 
Nathan H Fowler, MD
Director of Clinical Investigation and
Translational Research
Lead, Phase I and Indolent
Research Groups
Department of Lymphoma/Myeloma
The University of Texas
MD Anderson Cancer Center
Houston, Texas
 
Gilles A Salles, MD, PhD
Professor of Medicine
Université Claude Bernard
Head of the Hematology Department
Hospices Civils de Lyon
Lyon, France
 
EDITOR
 
Neil Love, MD
Research To Practice
Miami, Florida